Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

Cancer-fighting spinoff from UAB grows through IPO, clinical trial and new lab space in Birmingham

At UAB, the company IN8bio Inc. is running a Phase I clinical trial to treat glioblastoma multiforme, the most aggressive type of cancer that originates in the brain.

At UAB, the company IN8bio Inc. is running a Phase I clinical trial to treat glioblastoma multiforme, the most aggressive type of cancer that originates in the brain.

Heart repair and regeneration after a heart attack — a review

Basic and translational research in this field aims to repair heart injury and prevent the heart failure that often follows a heart attack.

Basic and translational research in this field aims to repair heart injury and prevent the heart failure that often follows a heart attack.

How the pathogen Mycobacterium tuberculosis secretes and trafficks its only known exotoxin

How the pathogen Mycobacterium tuberculosis secretes and trafficks its only known exotoxin
Bacteria use molecular machines to move proteins, including toxins, across cell membranes. M. tuberculosis, which kills more than 1 million people a year, uses the ESX-4 type VII secretion system to transports its potent exotoxin.

Hypoxia imaging and combination therapy aid immunotherapy treatment of solid tumors

Preclinical experiments show how to identify non-responding tumors and improve their response to immunotherapy, using two investigational new drugs that are permitted for human use. Physicians could immediately start investigational research in patients to test the effectiveness of this personalized approach.
Preclinical experiments show how to identify non-responding tumors and improve their response to immunotherapy, using two investigational new drugs that are permitted for human use. Physicians could immediately start investigational research in patients to test the effectiveness of this personalized approach.

2021 Marchase Award winner Cherrington fights health disparities and chronic disease

The latest grant for Andrea Cherrington, M.D., is $21.7 million over five years from the National Institute on Minority Health and Health Disparities to improve chronic disease outcomes for Black Americans in the Deep South.

The latest grant for Andrea Cherrington, M.D., is $21.7 million over five years from the National Institute on Minority Health and Health Disparities to improve chronic disease outcomes for Black Americans in the Deep South.

New life sciences fund announced to spur UAB innovation commercialization

The life sciences fund will focus on development of early-stage UAB technologies and startup companies.
The life sciences fund will focus on development of early-stage UAB technologies and startup companies.

Slow release of a drug, TT-10, improves heart attack recovery in a mouse model

Slow release of a drug, TT-10, improves heart attack recovery in a mouse model

Release of TT-10 from nanoparticles improved heart function after a heart attack, accompanied by increased cardiomyocyte proliferation and smaller infarct size.

UAB researchers are part of a $3 million award to learn how to better treat lupus in Black patients

Lupus, an autoimmune disease that can attack any part of the body, can be confounding because patients often respond differently to the same treatment, and they vary widely in the severity of their symptoms.
Lupus, an autoimmune disease that can attack any part of the body, can be confounding because patients often respond differently to the same treatment, and they vary widely in the severity of their symptoms.

Individual donor strains do not show link between fecal microbe transplantation and successful melanoma immunotherapy

Fecal-dominant donor microbes in the recipient patients after fecal microbe transplantation did not correlate with response to anti-PD-1 therapy.

Fecal-dominant donor microbes in the recipient patients after fecal microbe transplantation did not correlate with response to anti-PD-1 therapy.

Novel small molecule potently attenuates neuroinflammation in brain and glial cells

Limiting neuroinflammation may represent a promising new approach to treat neurological diseases driven by neuroinflammation, such as stroke, spinal cord injury and neuropathic pain.
Limiting neuroinflammation may represent a promising new approach to treat neurological diseases driven by neuroinflammation, such as stroke, spinal cord injury and neuropathic pain.
Page 12 of 50